```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable laboratory compound extensively employed in thrombosis studies . This antibody fragment specifically targets the glycoprotein IIb/IIIa receptor on platelets , inhibiting clot formation . Consequently , it's Recombinant abciximab often investigated as a method to explore the pathways underlying clotting and to evaluate the efficacy of anticoagulant therapies. Supply is typically controlled to institutional settings.
```
Abciximab Drug Research: Utilizing C7E3 Antibody and 143653-53-6 in Scientific Assessments
Ongoing studies into abciximab, a platelet aggregation inhibitor, frequently utilizes the monoclonal antibody C7E3 and the molecule identified as 143653-53-6. These materials are instrumental for examining abciximab's biological activity, evaluating its therapeutic effect in various clinical settings, and exploring potential biomarkers of treatment response. Continued exploration leveraging these particular reagents is predicted to generate valuable insights for optimizing therapeutic strategies related to cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Research Possibilities with the Drug Abciximab 143653-53-6 using C7E3
Recent work indicate that this antiplatelet agent (identified as 143653-53-6) holds significant investigative promise, particularly when associated with a C7E3 construct. Preliminary observations suggested that this combination could boost therapeutic outcomes in multiple cardiovascular settings. Further examination is directed on defining the exact process of action between the antiplatelet medication and C7E3, encompassing analysis of thrombocyte clumping and arterial preservation.
- Current investigation work aim to refine delivery approaches.
- Animal models are are being applied to more confirm these propositions.
- Patient assessments might be required to fully determine patient effectiveness.
```
Abciximab (C7E3) for Research: Specifications and Details (143653-53-6)
Researchers requiring this antibody for in vitro research should meticulously assess integrity and precise characteristics. Material 143653-53-6 is typically provided as a solid powder and thorough analytical documentation including identity by LC-MS, binding affinity assays, and bacterial endotoxin testing must be available. Ensure the manufacturer's documentation specifies acceptable values for contaminants and meets established quality assurance standards .
Pharmaceutical-Grade Abciximab Details & Stock
Acquiring laboratory-grade Abciximab, specifically referencing the compound C7E3 and identified by the catalog number 143653-53-6, requires careful consideration of its manufacturer. This glycoprotein is frequently utilized in cell-based experiments, particularly those focused on platelet clumping and thrombosis . Available suppliers offer this substance in varying volumes, typically ranging from milligram to significant bulk supplies. Please recommend reviewing the report of testing to verify purity and suitability for your specific application . Furthermore , confirm the expiration date before purchasing to maintain ideal effectiveness.
- Common Purity: >95%
- Storage Conditions: -20°C or controlled conditions
- Intended Purpose: Platelet Clumping Suppression Studies